CHMP January 2026 Approvals: Expanding Access t...

By João L. Carapinha

February 2, 2026

CHMP January 2026 Approvals Signal Expanded Access to Innovative Therapies The
Accelerating FAST-EU Clinical Trials
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare
Arexvy RSV Vaccine Expansion: Broader Access and Impact on Adult Health Outcomes